This guideline covers medicines support for adults (aged 18 and over) who are receiving social care in the community. It aims to ensure that people who receive social care are supported to take and look after their medicines effectively and safely at home. It gives advice on assessing if people need help with managing their medicines, who should provide medicines support and how health and social care staff should work together.
This guideline covers good practice for developing and updating local formularies in line with statutory requirements. It supports developing formularies that reflect local needs, reduce variation in prescribing, and allow rapid adoption of new medicines and treatments.
This guideline covers good practice for developing, authorising, using and updating patient group directions. It also offers advice on deciding whether a patient group direction is needed.
This guideline covers systems and processes for using and managing controlled drugs safely in all NHS settings except care homes. It aims to improve working practices to comply with legislation and have robust governance arrangements. It also aims to reduce the safety risks associated with controlled drugs.
This guideline covers the effective use of antimicrobials (including antibiotics) in children, young people and adults. It aims to change prescribing practice to help slow the emergence of antimicrobial resistance and ensure that antimicrobials remain an effective treatment for infection.
Evidence-based recommendations on adefovir dipivoxil (Hepsera) and peginterferon alfa-2a (Pegasys) for the treatment of chronic hepatitis B
Evidence-based recommendations on HealOzone (ozone-releasing device) for treating tooth decay (occlusal pit/fissure caries/root caries)
Evidence-based recommendations on imatinib for treating unresectable and/or metastatic gastrointestinal stromal tumours (GIST/soft tissue sarcoma)
Evidence-based recommendations on laparoscopic (keyhole) surgery for repairing inguinal hernia (hernia in groin)
Evidence-based recommendations on non-steroidal tacrolimus and pimecrolimus for treating atopic eczema (atopic dermatitis)
Evidence-based recommendations on the frequency of application of topical corticosteroids for treating atopic eczema (atopic dermatitis)
Evidence-based recommendations on peginterferon beta-1a (Plegridy) for treating relapsing–remitting multiple sclerosis in adults
Evidence based recommendations on patiromer (Veltassa) for treating hyperkalaemia in adults
Evidence-based recommendations on sotagliflozin with insulin for treating type 1 diabetes in adults with a body mass index (BMI) of at least 27 kg/m2
Evidence-based recommendations on osimertinib (Tagrisso) for untreated locally advanced or metastatic EGFR mutation-positive non-small-cell lung cancer (NSCLC)
Evidence-based recommendations on olaparib (Lynparza) for relapsed platinum-sensitive ovarian, fallopian tube or primary peritoneal cancer in adults with a
Evidence-based recommendations on palbociclib (Ibrance) with fulvestrant for hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
NICE is unable to make a recommendation about the use in the NHS of atezolizumab (Tecentriq) with carboplatin and nab-paclitaxel for untreated advanced NSCLC
Evidence-based recommendations on lusutrombopag (Mulpleo) for severe thrombocytopenia in adults with chronic liver disease needing a planned invasive procedure
Evidence-based recommendations on ranibizumab (Lucentis) for treating diabetic macular oedema
NICE is unable to make a recommendation about the use in the NHS of tadalafil for treating symptoms associated with benign prostatic hyperplasia...
Evidence-based recommendations on vinflunine (Javlor) for the treatment of advanced or metastatic transitional cell carcinoma of the urothelial tract
NICE is unable to make a recommendation about the use in the NHS of decitabine for the treatment of acute myeloid leukaemia because no evidence...
Evidence-based recommendations on ipilimumab (Yervoy) for previously treated advanced (unresectable or metastatic) melanoma
Evidence-based recommendations on ivabradine (Procoralan) for treating chronic heart failure
Evidence-based recommendations on mannitol dry powder for inhalation (Bronchitol) for treating cystic fibrosis (CF)
Evidence-based recommendations on denosumab (XGEVA) for the prevention of skeletal-related events in adults with bone metastases from solid tumours
Evidence-based recommendations on alteplase (Actilyse) for treating acute ischaemic stroke (AIS)
Evidence-based recommendations on bevacizumab (Avastin) in combination with capecitabine for the first-line treatment of metastatic breast cancer
Evidence-based recommendations on rivaroxaban (Xarelto) for treating deep vein thrombosis (DVT) and preventing recurrent DVT and pulmonary embolism
Evidence-based recommendations on botulinum toxin type A (Botox) for the prevention of headaches in adults with chronic migraine
Evidence-based recommendations on abiraterone (Zytiga) for castration-resistant metastatic prostate cancer in adults previously treated with docetaxel
Evidence-based recommendations on sofosbuvir (Sovaldi) for treating some types of chronic hepatitis C (HCV)
Evidence-based recommendations on infliximab (Remicade, Inflectra, Remsima) adalimumab (Humira) and golimumab (Simponi) for ulcerative colitis after..
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for treatment and secondary prevention of deep vein thrombosis (DVT) or pulmonary embolism
Evidence-based recommendations on imatinib (Glivec) for adjuvant treatment of gastrointestinal stromal tumours (cancers in the digestive track)
Evidence-based recommendations on nalmefene (Selincro) for reducing alcohol consumption in people with alcohol dependence
Evidence-based recommendations on lenalidomide (Revlimid) for myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality
Evidence-based recommendations on ipilimumab (YERVOY) for treating previously untreated advanced (unresectable or metastatic) melanoma (skin cancer)
Evidence-based recommendations on the use of fludarabine for B-cell chronic lymphocytic leukaemia (CLL)
Evidence-based recommendations on dapagliflozin (Forxiga) in combination therapy for treating type 2 diabetes in adults
Evidence-based recommendations on rivaroxaban (Xarelto) for treating pulmonary embolism and preventing recurrent venous thromboembolism
NICE is unable to recommend the use in the NHS of loxapine inhalation for treating acute agitation and disturbed behaviours associated with
Evidence-based recommendations on bevacizumab (Avastin) in combination with gemcitabine and carboplatin for treating the first recurrence of
Evidence-based recommendations on bevacizumab (Avastin) in combination with paclitaxel and carboplatin for first-line treatment of advanced ovarian cancer
Evidence-based recommendations on ranibizumab (Lucentis) for treating sight problems caused by macular oedema secondary to retinal vein occlusion
NICE is unable to recommend the use in the NHS of canakinumab for treating gouty arthritis attacks and reducing the frequency of subsequent attacks
Evidence-based recommendations on percutaneous vertebroplasty and percutaneous balloon kyphoplasty for osteoporotic vertebral compression fractures
Evidence-based recommendations on omalizumab (Xolair) for treating severe persistent allergic asthma
NICE is unable to recommend the use in the NHS of methylnaltrexone for treating opioid-induced bowel dysfunction in people with advanced illness...